Avoro Capital Advisors Reduces $51M in PTC Therapeutics, Inc. ($PTCT)

Avoro Capital Advisors has sold its entire stake in PTC Therapeutics, Inc. (NasdaqGS: PTCT), according to its latest Form 13F filing with the SEC. The firm disposed of all 685,000 shares it previously held, marking a 100% reduction in its position. This filing reflects Avoro's holdings as of the end of the reporting period and may not represent its current position.

What Changed in Avoro Capital Advisors' PTC Therapeutics Position

Avoro Capital Advisors reduced its holdings in PTC Therapeutics from 685,000 shares to zero, a complete exit from the company. This move involved selling 685,000 shares, reflecting a 100% decrease in its stake. The filing did not disclose the value of the position at the time of the sale.

Other Institutional Activity in PTC Therapeutics

Other institutional investors have been active in PTC Therapeutics. BlackRock, Inc. increased its holdings by 169,652 shares, bringing its total to 12,948,717 shares valued at approximately $882.2 million. Janus Henderson Group PLC significantly boosted its stake by 2,342,101 shares, ending with 7,193,433 shares worth about $490 million. Vanguard Portfolio Management LLC initiated a new position with 4,804,594 shares valued at $327.3 million. Meanwhile, State Street Corp added 140,393 shares, resulting in a total of 4,346,519 shares worth $296.1 million.

PTC Therapeutics Stock Snapshot

Shares of PTC Therapeutics traded at $75.14. The company has a market cap of approximately $6.23 billion and a forward P/E ratio of 27. Its beta is 0.549, indicating lower volatility compared to the broader market. The stock's 52-week range is between $43.18 and $87.50, with a 50-day moving average of $70.42 and a 200-day moving average of $69.76. PTC Therapeutics maintains a current ratio of 2.44 and a quick ratio of 2.29.

Recent Earnings

PTC Therapeutics reported revenues of $827.1 million, though it experienced a revenue decline of 7.68%. The company posted a negative net margin of 22.58% and isn't currently profitable, so it doesn't have a meaningful P/E ratio. Its next earnings report is expected on August 6, 2026.

Insider Buying and Selling at PTC Therapeutics, Inc.

Recent insider activity at PTC Therapeutics included several trades by Chief Business Officer Eric Pauwels on June 10, 2026. Pauwels sold 21,277 shares at an average price of $75.00 under a planned sale and 17,566 shares at $18.01. Additionally, Executive VP and CLO Mark Elliott Boulding made transactions on May 15, 2026, selling 2,812 shares at $72.18 under a planned sale and buying the same number of shares at $25.69.

Analysts Set New Price Targets

Analysts have been active on PTC Therapeutics. On June 9, 2026, Citigroup assumed coverage with a buy rating and a price target of $108. Jefferies upgraded the stock to a buy with an $85 target on May 27, 2026. TD Cowen also upgraded it to buy with a $90 target on May 8, 2026. The consensus among analysts suggests a buy recommendation with a mean price target of $93.93, based on 14 opinions.

About PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company based in Warren, New Jersey. The firm focuses on developing and selling treatments for rare diseases. Notable products include Translarna and Emflaza for Duchenne muscular dystrophy and Evrysdi for spinal muscular atrophy. The company is also working on a pipeline of potential treatments for other rare conditions, collaborating with organizations like F. Hoffman-La Roche and Novartis Pharmaceuticals.

Bottom Line

Avoro Capital Advisors' complete exit from PTC Therapeutics is a significant move, reflecting its strategic shift. Investors often track such filings to gauge institutional sentiment, though it's important to remember these reports are backward-looking. PTC Therapeutics continues to be a company of interest with active insider trading and positive analyst coverage.